The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 17, 2021

Filed:

Jul. 21, 2016
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Gregory J. Opiteck, Milltown, NJ (US);

Peggy H. Wong, Summit, NJ (US);

Joshua McElwee, Jamaica Plains, MA (US);

Devan V. Mehrotra, Lansdale, PA (US);

Steven Greenberg, East Hanover, NJ (US);

Zifang Guo, Audubon, PA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01); A61K 31/437 (2006.01); A61K 31/47 (2006.01); C07D 215/14 (2006.01); C07D 471/04 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6883 (2013.01); A61K 31/437 (2013.01); A61K 31/47 (2013.01); A61K 45/06 (2013.01); C07D 215/14 (2013.01); C07D 471/04 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01);
Abstract

The present invention provides genetic markers on human chromosome 1 that are associated with a beneficial response to CRTH2 receptor antagonists. These CRTH2 receptor antagonist response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with CRTH2 receptor antagonist compositions and drug products, in methods of treating patients having a disease susceptible to treatment with a CRTH2 receptor antagonist, and in methods for selecting the most appropriate therapy for such patients.


Find Patent Forward Citations

Loading…